



# SAFETY DATA SHEET

Revision Date 16-Jul-2019

Version 1

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

### Product identifier

**Product Name** SAPHRIS

### Other means of identification

**Product Code** FG00158

**Synonyms** Asenapine Sublingual Tablets

### Recommended use of the chemical and restrictions on use

**Recommended Use** Schizophrenia in adults. Bipolar I disorder o Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age o Adjunctive treatment to lithium or valproate in adults o Maintenance monotherapy treatment in adults

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

### Details of the supplier of the safety data sheet

#### **Manufacturer**

Allergan plc  
5 Giralda Farms  
Madison, NJ USA 07940  
+1-800-272-5525

#### **E-mail address**

SDS@Allergan.com

### Emergency telephone number

#### **Emergency Telephone**

Call CHEMTREC Day or Night  
Within USA or Canada: 1-800-424-9300  
Outside USA and Canada: +1-703-741-5970 (collect calls accepted)

## 2. HAZARDS IDENTIFICATION

### Classification

#### **OSHA Regulatory Status**

This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Carcinogenicity	Category 2
Reproductive toxicity	Category 2

### Label elements

#### **Emergency Overview**

#### **Warning**

#### **Hazard statements**

H351 - Suspected of causing cancer  
H361 - Suspected of damaging fertility or the unborn child



<b>Appearance</b> Tablet	<b>Physical state</b> Solid	<b>Odor</b> No information available
<b>Chemical Name</b> Asenapine	<b>Symptoms</b> The most common adverse events associated with asenapine were restlessness, decreased sensitivity of the mouth, sleepiness, dizziness, and weight increase.	
<b>Chemical Name</b> Asenapine	<b>Medical Conditions Aggravated by Exposure</b> Contradictions include severe hepatic impairment and hypersensitivity to SAPHRIS (asenapine), or to any components in the formulation.	

**Precautionary statements**

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/ container to an approved waste disposal plant

**Other Information**

Unknown Acute Toxicity

81% of the mixture consists of ingredient(s) of unknown toxicity

Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS No.	EINECS	Weight-%
Asenapine	85650-56-2	288-064-8	15 - 40*
GELATIN TYPE A NF	9000-70-8	232-554-6	10 - 30*
Sucralose NF Micronized	56038-13-2	259-952-2	10 - 30*
MANNITOL USP	69-65-8	200-711-8	10 - 30*
PROPYLENE GLYCOL USP	57-55-6	200-338-0	1 - 5*

\*The exact percentage (concentration) of composition has been withheld as a trade secret.

### 4. FIRST AID MEASURES

**First aid measures**

<b>Eye contact</b>	Rinse immediately with plenty of water and seek medical advice.
<b>Skin Contact</b>	Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.
<b>Inhalation</b>	Remove to fresh air.
<b>Ingestion</b>	Consult a physician if necessary.

**Chemical Name** **Note to physicians**

Asenapine

There is no specific antidote to SAPHRIS. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Consult with a Certified Poison Control Center for up-to-date guidance and advice on the management of overdose (1-800-222-1222.) Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of SAPHRIS-induced alpha blockade). In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

## 5. FIRE-FIGHTING MEASURES

### Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

### Unsuitable extinguishing media

None known.

### Specific hazards arising from the chemical

Fire may produce irritating, corrosive and/or toxic gases.

### Explosion data

#### **Sensitivity to Mechanical Impact**

Not impact sensitive.

#### **Sensitivity to Static Discharge**

Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

### Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

## 6. ACCIDENTAL RELEASE MEASURES

### **Personal precautions**

Use personal protection recommended in Section 8. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.

### **Environmental precautions**

See Section 12 for additional ecological information.

### **Methods for containment**

Prevent further leakage or spillage if safe to do so.

### **Methods for cleaning up**

Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly.

## 7. HANDLING AND STORAGE

### **Advice on safe handling**

Avoid contact with skin, eyes or clothing. Avoid generation of dust. Do not eat, drink or smoke when using this product.

### **Storage Conditions**

Keep containers tightly closed in a dry, cool and well-ventilated place. Store away from incompatible materials.

### **Incompatible materials**

None known based on information supplied.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Control parameters**

**Exposure Guidelines** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Chemical Name	ACGIH TLV	OSHA PEL	NIOSH IDLH	Allergan OEL (ug/m <sup>3</sup> )
Asenapine 85650-56-2	N/A	N/A	N/A	2

**Appropriate engineering controls**

**Engineering Controls** The health hazard risks of handling this material are dependent on factors, such as physical form and quantity. Site specific risk assessments should be conducted to determine the appropriate exposure control measures. Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

**Individual protection measures, such as personal protective equipment**

**Eye/face protection** No eye protection is normally needed during medical administration of this product. During operations in which dusts of the product may be generated, safety glasses should be considered.

**Skin and body protection** During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab coat, etc.).

**Respiratory protection** Respiratory protection is generally not needed during routine conditions of use of this product. If respiratory protection is needed, use only respiratory protection authorized under appropriate regional regulations.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

**Information on basic physical and chemical properties**

<b>Physical state</b>	Solid	<b>Appearance</b>	Tablet
<b>Color</b>	No information available	<b>Odor</b>	No information available
<b>Odor threshold</b>	No information available		

<u>Property</u>	<u>Values</u>
pH	No information available
Melting point/freezing point	No information available
Boiling point / boiling range	No information available
Flash point	No information available
Evaporation rate	No information available
Flammability (solid, gas)	No information available
Flammability Limit in Air	
Upper flammability limit:	No information available
Lower flammability limit:	No information available
Vapor pressure	No information available
Vapor density	No information available
Specific Gravity	No information available
Water solubility	No information available
Solubility in other solvents	No information available
Partition coefficient	No information available
Autoignition temperature	No information available
Decomposition temperature	No information available
Explosive properties	No information available
Oxidizing properties	No information available

**Other Information**

Molecular weight	No information available
VOC Content (%)	No information available
Density	No information available
Bulk density	No information available

**10. STABILITY AND REACTIVITY****Reactivity**

Not defined As Reactive substance

**Chemical stability**

Stable under normal conditions.

**Possibility of Hazardous Reactions**

None under normal processing.

**Conditions to avoid**

Aerosol formation.

**Incompatible materials**

None known based on information supplied.

**Hazardous Decomposition Products**

None known based on information supplied.

**11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure****Acute toxicity**

Chemical Name	Inhalation	Eye contact	Skin Contact	Ingestion
Asenapine	Move to fresh air. If symptoms persist, call a physician.	See Symptoms for more information.	See Symptoms for more information.	See Symptoms for more information.

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
MANNITOL USP	= 13500 mg/kg ( Rat )	N/A	N/A
PROPYLENE GLYCOL USP	= 19000 mg/kg (Dog)	= 20800 mg/kg ( Rabbit )	N/A

**Delayed and immediate effects as well as chronic effects from short and long-term exposure**

Chemical Name	Germ cell mutagenicity	Carcinogenicity	Reproductive toxicity	Effects on or via lactation
Asenapine	Negative for genotoxicity in vitro and in vivo tests.	Chronic Exposure or Carcinogenicity/ In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the maximum recommended human dose (MRHD) of 10 mg twice daily. The incidence of malignant lymphomas was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving	Not teratogenic in rats or rabbits. Studies in rats have not shown fertility impairment. increases in post-implantation loss and early pup deaths were seen at all doses, and decreases in subsequent pup survival and weight gain were seen at the two higher doses in rats.	No information available

		the MRHD. The mouse strain used has a high and variable incidence of malignant lymphomas, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type.		
--	--	---	--	--

**Target Organ Effects** Central nervous system.

**Numerical measures of toxicity - Product Information**

**Unknown Acute Toxicity** 81% of the mixture consists of ingredient(s) of unknown toxicity

The following values are calculated based on chapter 3.1 of the GHS document .

ATEmix (oral) 14376 mg/kg  
 ATEmix (dermal) 98800 mg/kg

**12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

96% of the mixture consists of component(s) of unknown hazards to the aquatic environment

Chemical Name	Algae/aquatic plants	Fish	Crustacea
PROPYLENE GLYCOL USP 57-55-6	19000: 96 h Pseudokirchneriella subcapitata mg/L EC50	41 - 47: 96 h Oncorhynchus mykiss mL/L LC50 static 51600: 96 h Oncorhynchus mykiss mg/L LC50 static 51400: 96 h Pimephales promelas mg/L LC50 static 710: 96 h Pimephales promelas mg/L LC50	1000: 48 h Daphnia magna mg/L EC50 Static 10000: 24 h Daphnia magna mg/L EC50

Chemical Name	Persistence and degradability	Bioaccumulation	Mobility	Partition coefficient
Asenapine 85650-56-2	N/A	Based on the BCF, the potential for bioaccumulation in aquatic organisms is high.	Immobile	4.77

**Other adverse effects** No information available

**13. DISPOSAL CONSIDERATIONS**

**Waste treatment methods**

**Disposal of wastes** Disposal should be in accordance with applicable regional, national and local laws and regulations.

**Contaminated packaging** Do not reuse container. Dispose of contents/containers in accordance with local regulations.

**14. TRANSPORT INFORMATION**

**DOT** Not regulated

**TDG** Not regulated

**ICAO (air)** Not regulated

IATA Not regulatedIMDG Not regulatedADR Not regulatedADN Not regulated**15. REGULATORY INFORMATION****International Inventories**

<b>TSCA</b>	Not Listed
<b>DSL/NDSL</b>	Not Listed
<b>EINECS/ELINCS</b>	Listed

**Legend:****TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances**US Federal Regulations****SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372

**SARA 311/312 Hazard Categories**

<b>Acute health hazard</b>	No
<b>Chronic Health Hazard</b>	No
<b>Fire hazard</b>	No
<b>Sudden release of pressure hazard</b>	No
<b>Reactive Hazard</b>	No

**CWA (Clean Water Act)**

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42)

**CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material

**US State Regulations****California Proposition 65**

This product does not contain any Proposition 65 chemicals

**U.S. State Right-to-Know Regulations**

<b>Chemical Name</b>	<b>New Jersey</b>	<b>Massachusetts</b>	<b>Pennsylvania</b>
PROPYLENE GLYCOL USP 57-55-6	X	-	X

**16. OTHER INFORMATION****Revision Date** 16-Jul-2019**Revision Note** No information available**Disclaimer**

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing,

storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

**End of Safety Data Sheet**